Our Technology

The combined medical advances of superior sampling and advanced 3D imaging means WATS3D has far-reaching implications for protecting your health. Should pre-cancerous cells be present, they are now much more likely to be detected so they can be removed or destroyed before they can progress to Esophageal Cancer. This is the simple story behind a sophisticated technology that has already helped make Esophageal Cancer a potentially preventable disease.

What follows is a more detailed overview of how our technology works.

The role of WATS3D, as part of an “Upper Endoscopy,”  starts as a superior, patented, tissue sampling instrument that is used to painlessly obtain samples from the esophagus in order to test for the presence of pre-cancerous cells.

Once the sample is received at the CDx Diagnostics laboratory, specimens are stained and examined by an advanced computer image analysis system that synthesizes computer imaging, artificial intelligence, molecular biology and three-dimensional cytopathology to detect pre-cancerous change earlier and more reliably than with prior methods.

All of the approximately 100,000 cells on the slide are scanned using a proprietary imaging and computer network that allows a three-dimensional view. Several tests are performed on each of the cells on the slide. Cells of particular interest are then rescanned at a higher resolution to provide a more detailed view. The approximately 200 “most suspicious” cells are then flagged for the pathologist as a starting point for analysis. A pathologist renders the final result following both computer-assisted and manual microscopic examination of the slide.

The high sensitivity of WATS3D is, in part, due to the proprietary computer imaging system that is based on an algorithm developed as part of the “Star Wars” missile defense program. This neural network performs sophisticated tests on every cell on the slide, allowing any sign of potential abnormality to be caught at the earliest possible stage..

The computer video microscope output is used by the pathologist along with a standard microscopic evaluation of each specimen before rendering a final diagnosis.

Our tissue collection takes only a few minutes, is widely reimbursed, and addresses a recognized critical gap in the current diagnostic standard of care that results in thousands of otherwise unnecessary Esophageal Cancer deaths each year. Routine clinical use of CDx testing in the esophagus has already prevented thousands of cancers.